Clinical Trials · NCT02294786

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Name: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 2Octreotide

Phase: Phase 2
Recruitment status: Terminated
Sponsor: Novartis Pharmaceuticals
Enrollment: 62
Start date: Dec 2014
Locations: 17 sites, 5 countries
Primary endpoint: Proportion of Subjects Experiencing Diarrhoea of Grade 2 and Above (up to 24 Weeks)

View Octreotide compound reference